

Adalimumab, Infliximab And Etanercept Biosimilars Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/A4238D2DD30AEN.html>

Date: January 2022

Pages: 78

Price: US\$ 3,250.00 (Single User License)

ID: A4238D2DD30AEN

Abstracts

Biosimilar is a biologic medical product which is highly similar to another already approved biological medicine.

This report contains market size and forecasts of Adalimumab, Infliximab And Etanercept Biosimilars in global, including the following market information:

Global Adalimumab, Infliximab And Etanercept Biosimilars Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global Adalimumab, Infliximab And Etanercept Biosimilars Market Sales, 2017-2022, 2023-2028, (K Units)

Global top five Adalimumab, Infliximab And Etanercept Biosimilars companies in 2021 (%)

The global Adalimumab, Infliximab And Etanercept Biosimilars market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Adalimumab Biosimilars Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Adalimumab, Infliximab And Etanercept Biosimilars

include Boehringer Ingelheim, Abbvie, Cipla Ltd, Hetero Drugs Limited, Pfizer, Novartis, Samsung Bioepis(Samsung Biologics), Amgen and Celltrion Healthcare, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Adalimumab, Infliximab And Etanercept Biosimilars manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Adalimumab, Infliximab And Etanercept Biosimilars Market, by Type, 2017-2022, 2023-2028 (\$ Millions) & (K Units)

Global Adalimumab, Infliximab And Etanercept Biosimilars Market Segment Percentages, by Type, 2021 (%)

Adalimumab Biosimilars

Infliximab Biosimilars

Etanercept Biosimilars

Global Adalimumab, Infliximab And Etanercept Biosimilars Market, by Application, 2017-2022, 2023-2028 (\$ Millions) & (K Units)

Global Adalimumab, Infliximab And Etanercept Biosimilars Market Segment Percentages, by Application, 2021 (%)

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Global Adalimumab, Infliximab And Etanercept Biosimilars Market, By Region and

Country, 2017-2022, 2023-2028 (\$ Millions) & (K Units)

Global Adalimumab, Infliximab And Etanercept Biosimilars Market Segment
Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Adalimumab, Infliximab And Etanercept Biosimilars revenues in global market, 2017-2022 (Estimated), (\$ millions)

Key companies Adalimumab, Infliximab And Etanercept Biosimilars revenues share in global market, 2021 (%)

Key companies Adalimumab, Infliximab And Etanercept Biosimilars sales in global market, 2017-2022 (Estimated), (K Units)

Key companies Adalimumab, Infliximab And Etanercept Biosimilars sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Boehringer Ingelheim

Abbvie

Cipla Ltd

Hetero Drugs Limited

Pfizer

Novartis

Samsung Bioepis(Samsung Biologics)

Amgen

Celltrion Healthcare

Mylan

HETERO

Glenmark Pharmaceuticals

Emcure Pharmaceuticals

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Adalimumab, Infliximab And Etanercept Biosimilars Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Adalimumab, Infliximab And Etanercept Biosimilars Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL ADALIMUMAB, INFLIXIMAB AND ETANERCEPT BIOSIMILARS OVERALL MARKET SIZE

- 2.1 Global Adalimumab, Infliximab And Etanercept Biosimilars Market Size: 2021 VS 2028
- 2.2 Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue, Prospects & Forecasts: 2017-2028
- 2.3 Global Adalimumab, Infliximab And Etanercept Biosimilars Sales: 2017-2028

3 COMPANY LANDSCAPE

- 3.1 Top Adalimumab, Infliximab And Etanercept Biosimilars Players in Global Market
- 3.2 Top Global Adalimumab, Infliximab And Etanercept Biosimilars Companies Ranked by Revenue
- 3.3 Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue by Companies
- 3.4 Global Adalimumab, Infliximab And Etanercept Biosimilars Sales by Companies
- 3.5 Global Adalimumab, Infliximab And Etanercept Biosimilars Price by Manufacturer (2017-2022)
- 3.6 Top 3 and Top 5 Adalimumab, Infliximab And Etanercept Biosimilars Companies in Global Market, by Revenue in 2021
- 3.7 Global Manufacturers Adalimumab, Infliximab And Etanercept Biosimilars Product Type
- 3.8 Tier 1, Tier 2 and Tier 3 Adalimumab, Infliximab And Etanercept Biosimilars Players

in Global Market

3.8.1 List of Global Tier 1 Adalimumab, Infliximab And Etanercept Biosimilars Companies

3.8.2 List of Global Tier 2 and Tier 3 Adalimumab, Infliximab And Etanercept Biosimilars Companies

4 SIGHTS BY PRODUCT

4.1 Overview

4.1.1 By Type - Global Adalimumab, Infliximab And Etanercept Biosimilars Market Size Markets, 2021 & 2028

4.1.2 Adalimumab Biosimilars

4.1.3 Infliximab Biosimilars

4.1.4 Etanercept Biosimilars

4.2 By Type - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue & Forecasts

4.2.1 By Type - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue, 2017-2022

4.2.2 By Type - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue, 2023-2028

4.2.3 By Type - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue Market Share, 2017-2028

4.3 By Type - Global Adalimumab, Infliximab And Etanercept Biosimilars Sales & Forecasts

4.3.1 By Type - Global Adalimumab, Infliximab And Etanercept Biosimilars Sales, 2017-2022

4.3.2 By Type - Global Adalimumab, Infliximab And Etanercept Biosimilars Sales, 2023-2028

4.3.3 By Type - Global Adalimumab, Infliximab And Etanercept Biosimilars Sales Market Share, 2017-2028

4.4 By Type - Global Adalimumab, Infliximab And Etanercept Biosimilars Price (Manufacturers Selling Prices), 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Adalimumab, Infliximab And Etanercept Biosimilars Market Size, 2021 & 2028

5.1.2 Hospital Pharmacies

5.1.3 Retail Pharmacies

5.1.4 Online Pharmacies

5.2 By Application - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue & Forecasts

5.2.1 By Application - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue, 2017-2022

5.2.2 By Application - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue, 2023-2028

5.2.3 By Application - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue Market Share, 2017-2028

5.3 By Application - Global Adalimumab, Infliximab And Etanercept Biosimilars Sales & Forecasts

5.3.1 By Application - Global Adalimumab, Infliximab And Etanercept Biosimilars Sales, 2017-2022

5.3.2 By Application - Global Adalimumab, Infliximab And Etanercept Biosimilars Sales, 2023-2028

5.3.3 By Application - Global Adalimumab, Infliximab And Etanercept Biosimilars Sales Market Share, 2017-2028

5.4 By Application - Global Adalimumab, Infliximab And Etanercept Biosimilars Price (Manufacturers Selling Prices), 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Adalimumab, Infliximab And Etanercept Biosimilars Market Size, 2021 & 2028

6.2 By Region - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue & Forecasts

6.2.1 By Region - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue, 2017-2022

6.2.2 By Region - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue, 2023-2028

6.2.3 By Region - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue Market Share, 2017-2028

6.3 By Region - Global Adalimumab, Infliximab And Etanercept Biosimilars Sales & Forecasts

6.3.1 By Region - Global Adalimumab, Infliximab And Etanercept Biosimilars Sales, 2017-2022

6.3.2 By Region - Global Adalimumab, Infliximab And Etanercept Biosimilars Sales, 2023-2028

6.3.3 By Region - Global Adalimumab, Infliximab And Etanercept Biosimilars Sales Market Share, 2017-2028

6.4 North America

6.4.1 By Country - North America Adalimumab, Infliximab And Etanercept Biosimilars Revenue, 2017-2028

6.4.2 By Country - North America Adalimumab, Infliximab And Etanercept Biosimilars Sales, 2017-2028

6.4.3 US Adalimumab, Infliximab And Etanercept Biosimilars Market Size, 2017-2028

6.4.4 Canada Adalimumab, Infliximab And Etanercept Biosimilars Market Size, 2017-2028

6.4.5 Mexico Adalimumab, Infliximab And Etanercept Biosimilars Market Size, 2017-2028

6.5 Europe

6.5.1 By Country - Europe Adalimumab, Infliximab And Etanercept Biosimilars Revenue, 2017-2028

6.5.2 By Country - Europe Adalimumab, Infliximab And Etanercept Biosimilars Sales, 2017-2028

6.5.3 Germany Adalimumab, Infliximab And Etanercept Biosimilars Market Size, 2017-2028

6.5.4 France Adalimumab, Infliximab And Etanercept Biosimilars Market Size, 2017-2028

6.5.5 U.K. Adalimumab, Infliximab And Etanercept Biosimilars Market Size, 2017-2028

6.5.6 Italy Adalimumab, Infliximab And Etanercept Biosimilars Market Size, 2017-2028

6.5.7 Russia Adalimumab, Infliximab And Etanercept Biosimilars Market Size, 2017-2028

6.5.8 Nordic Countries Adalimumab, Infliximab And Etanercept Biosimilars Market Size, 2017-2028

6.5.9 Benelux Adalimumab, Infliximab And Etanercept Biosimilars Market Size, 2017-2028

6.6 Asia

6.6.1 By Region - Asia Adalimumab, Infliximab And Etanercept Biosimilars Revenue, 2017-2028

6.6.2 By Region - Asia Adalimumab, Infliximab And Etanercept Biosimilars Sales, 2017-2028

6.6.3 China Adalimumab, Infliximab And Etanercept Biosimilars Market Size, 2017-2028

6.6.4 Japan Adalimumab, Infliximab And Etanercept Biosimilars Market Size, 2017-2028

6.6.5 South Korea Adalimumab, Infliximab And Etanercept Biosimilars Market Size,

2017-2028

6.6.6 Southeast Asia Adalimumab, Infliximab And Etanercept Biosimilars Market Size, 2017-2028

6.6.7 India Adalimumab, Infliximab And Etanercept Biosimilars Market Size, 2017-2028

6.7 South America

6.7.1 By Country - South America Adalimumab, Infliximab And Etanercept Biosimilars Revenue, 2017-2028

6.7.2 By Country - South America Adalimumab, Infliximab And Etanercept Biosimilars Sales, 2017-2028

6.7.3 Brazil Adalimumab, Infliximab And Etanercept Biosimilars Market Size, 2017-2028

6.7.4 Argentina Adalimumab, Infliximab And Etanercept Biosimilars Market Size, 2017-2028

6.8 Middle East & Africa

6.8.1 By Country - Middle East & Africa Adalimumab, Infliximab And Etanercept Biosimilars Revenue, 2017-2028

6.8.2 By Country - Middle East & Africa Adalimumab, Infliximab And Etanercept Biosimilars Sales, 2017-2028

6.8.3 Turkey Adalimumab, Infliximab And Etanercept Biosimilars Market Size, 2017-2028

6.8.4 Israel Adalimumab, Infliximab And Etanercept Biosimilars Market Size, 2017-2028

6.8.5 Saudi Arabia Adalimumab, Infliximab And Etanercept Biosimilars Market Size, 2017-2028

6.8.6 UAE Adalimumab, Infliximab And Etanercept Biosimilars Market Size, 2017-2028

7 MANUFACTURERS & BRANDS PROFILES

7.1 Boehringer Ingelheim

7.1.1 Boehringer Ingelheim Corporate Summary

7.1.2 Boehringer Ingelheim Business Overview

7.1.3 Boehringer Ingelheim Adalimumab, Infliximab And Etanercept Biosimilars Major Product Offerings

7.1.4 Boehringer Ingelheim Adalimumab, Infliximab And Etanercept Biosimilars Sales and Revenue in Global (2017-2022)

7.1.5 Boehringer Ingelheim Key News

7.2 Abbvie

7.2.1 Abbvie Corporate Summary

7.2.2 Abbvie Business Overview

7.2.3 Abbvie Adalimumab, Infliximab And Etanercept Biosimilars Major Product Offerings

Offerings

7.2.4 Abbvie Adalimumab, Infliximab And Etanercept Biosimilars Sales and Revenue in Global (2017-2022)

7.2.5 Abbvie Key News

7.3 Cipla Ltd

7.3.1 Cipla Ltd Corporate Summary

7.3.2 Cipla Ltd Business Overview

7.3.3 Cipla Ltd Adalimumab, Infliximab And Etanercept Biosimilars Major Product Offerings

Offerings

7.3.4 Cipla Ltd Adalimumab, Infliximab And Etanercept Biosimilars Sales and Revenue in Global (2017-2022)

7.3.5 Cipla Ltd Key News

7.4 Hetero Drugs Limited

7.4.1 Hetero Drugs Limited Corporate Summary

7.4.2 Hetero Drugs Limited Business Overview

7.4.3 Hetero Drugs Limited Adalimumab, Infliximab And Etanercept Biosimilars Major Product Offerings

7.4.4 Hetero Drugs Limited Adalimumab, Infliximab And Etanercept Biosimilars Sales and Revenue in Global (2017-2022)

7.4.5 Hetero Drugs Limited Key News

7.5 Pfizer

7.5.1 Pfizer Corporate Summary

7.5.2 Pfizer Business Overview

7.5.3 Pfizer Adalimumab, Infliximab And Etanercept Biosimilars Major Product Offerings

Offerings

7.5.4 Pfizer Adalimumab, Infliximab And Etanercept Biosimilars Sales and Revenue in Global (2017-2022)

7.5.5 Pfizer Key News

7.6 Novartis

7.6.1 Novartis Corporate Summary

7.6.2 Novartis Business Overview

7.6.3 Novartis Adalimumab, Infliximab And Etanercept Biosimilars Major Product Offerings

7.6.4 Novartis Adalimumab, Infliximab And Etanercept Biosimilars Sales and Revenue in Global (2017-2022)

7.6.5 Novartis Key News

7.7 Samsung Bioepis(Samsung Biologics)

- 7.7.1 Samsung Bioepis(Samsung Biologics) Corporate Summary
- 7.7.2 Samsung Bioepis(Samsung Biologics) Business Overview
- 7.7.3 Samsung Bioepis(Samsung Biologics) Adalimumab, Infliximab And Etanercept Biosimilars Major Product Offerings
- 7.7.4 Samsung Bioepis(Samsung Biologics) Adalimumab, Infliximab And Etanercept Biosimilars Sales and Revenue in Global (2017-2022)
- 7.7.5 Samsung Bioepis(Samsung Biologics) Key News
- 7.8 Amgen
 - 7.8.1 Amgen Corporate Summary
 - 7.8.2 Amgen Business Overview
 - 7.8.3 Amgen Adalimumab, Infliximab And Etanercept Biosimilars Major Product Offerings
 - 7.8.4 Amgen Adalimumab, Infliximab And Etanercept Biosimilars Sales and Revenue in Global (2017-2022)
 - 7.8.5 Amgen Key News
- 7.9 Celltrion Healthcare
 - 7.9.1 Celltrion Healthcare Corporate Summary
 - 7.9.2 Celltrion Healthcare Business Overview
 - 7.9.3 Celltrion Healthcare Adalimumab, Infliximab And Etanercept Biosimilars Major Product Offerings
 - 7.9.4 Celltrion Healthcare Adalimumab, Infliximab And Etanercept Biosimilars Sales and Revenue in Global (2017-2022)
 - 7.9.5 Celltrion Healthcare Key News
- 7.10 Mylan
 - 7.10.1 Mylan Corporate Summary
 - 7.10.2 Mylan Business Overview
 - 7.10.3 Mylan Adalimumab, Infliximab And Etanercept Biosimilars Major Product Offerings
 - 7.10.4 Mylan Adalimumab, Infliximab And Etanercept Biosimilars Sales and Revenue in Global (2017-2022)
 - 7.10.5 Mylan Key News
- 7.11 HETERO
 - 7.11.1 HETERO Corporate Summary
 - 7.11.2 HETERO Adalimumab, Infliximab And Etanercept Biosimilars Business Overview
 - 7.11.3 HETERO Adalimumab, Infliximab And Etanercept Biosimilars Major Product Offerings
 - 7.11.4 HETERO Adalimumab, Infliximab And Etanercept Biosimilars Sales and Revenue in Global (2017-2022)

7.11.5 HETERO Key News

7.12 Glenmark Pharmaceuticals

7.12.1 Glenmark Pharmaceuticals Corporate Summary

7.12.2 Glenmark Pharmaceuticals Adalimumab, Infliximab And Etanercept Biosimilars Business Overview

7.12.3 Glenmark Pharmaceuticals Adalimumab, Infliximab And Etanercept Biosimilars Major Product Offerings

7.12.4 Glenmark Pharmaceuticals Adalimumab, Infliximab And Etanercept Biosimilars Sales and Revenue in Global (2017-2022)

7.12.5 Glenmark Pharmaceuticals Key News

7.13 Emcure Pharmaceuticals

7.13.1 Emcure Pharmaceuticals Corporate Summary

7.13.2 Emcure Pharmaceuticals Adalimumab, Infliximab And Etanercept Biosimilars Business Overview

7.13.3 Emcure Pharmaceuticals Adalimumab, Infliximab And Etanercept Biosimilars Major Product Offerings

7.13.4 Emcure Pharmaceuticals Adalimumab, Infliximab And Etanercept Biosimilars Sales and Revenue in Global (2017-2022)

7.13.5 Emcure Pharmaceuticals Key News

8 GLOBAL ADALIMUMAB, INFLIXIMAB AND ETANERCEPT BIOSIMILARS PRODUCTION CAPACITY, ANALYSIS

8.1 Global Adalimumab, Infliximab And Etanercept Biosimilars Production Capacity, 2017-2028

8.2 Adalimumab, Infliximab And Etanercept Biosimilars Production Capacity of Key Manufacturers in Global Market

8.3 Global Adalimumab, Infliximab And Etanercept Biosimilars Production by Region

9 KEY MARKET TRENDS, OPPORTUNITY, DRIVERS AND RESTRAINTS

9.1 Market Opportunities & Trends

9.2 Market Drivers

9.3 Market Restraints

10 ADALIMUMAB, INFLIXIMAB AND ETANERCEPT BIOSIMILARS SUPPLY CHAIN ANALYSIS

10.1 Adalimumab, Infliximab And Etanercept Biosimilars Industry Value Chain

- 10.2 Adalimumab, Infliximab And Etanercept Biosimilars Upstream Market
- 10.3 Adalimumab, Infliximab And Etanercept Biosimilars Downstream and Clients
- 10.4 Marketing Channels Analysis
 - 10.4.1 Marketing Channels
 - 10.4.2 Adalimumab, Infliximab And Etanercept Biosimilars Distributors and Sales Agents in Global

11 CONCLUSION

12 APPENDIX

- 12.1 Note
- 12.2 Examples of Clients
- 12.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Key Players of Adalimumab, Infliximab And Etanercept Biosimilars in Global Market

Table 2. Top Adalimumab, Infliximab And Etanercept Biosimilars Players in Global Market, Ranking by Revenue (2021)

Table 3. Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue by Companies, (US\$, Mn), 2017-2022

Table 4. Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue Share by Companies, 2017-2022

Table 5. Global Adalimumab, Infliximab And Etanercept Biosimilars Sales by Companies, (K Units), 2017-2022

Table 6. Global Adalimumab, Infliximab And Etanercept Biosimilars Sales Share by Companies, 2017-2022

Table 7. Key Manufacturers Adalimumab, Infliximab And Etanercept Biosimilars Price (2017-2022) & (US\$/Unit)

Table 8. Global Manufacturers Adalimumab, Infliximab And Etanercept Biosimilars Product Type

Table 9. List of Global Tier 1 Adalimumab, Infliximab And Etanercept Biosimilars Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Adalimumab, Infliximab And Etanercept Biosimilars Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue (US\$, Mn), 2017-2022

Table 13. By Type - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue (US\$, Mn), 2023-2028

Table 14. By Type - Global Adalimumab, Infliximab And Etanercept Biosimilars Sales (K Units), 2017-2022

Table 15. By Type - Global Adalimumab, Infliximab And Etanercept Biosimilars Sales (K Units), 2023-2028

Table 16. By Application – Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2021 & 2028

Table 17. By Application - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue (US\$, Mn), 2017-2022

Table 18. By Application - Global Adalimumab, Infliximab And Etanercept Biosimilars

Revenue (US\$, Mn), 2023-2028

Table 19. By Application - Global Adalimumab, Infliximab And Etanercept Biosimilars Sales (K Units), 2017-2022

Table 20. By Application - Global Adalimumab, Infliximab And Etanercept Biosimilars Sales (K Units), 2023-2028

Table 21. By Region – Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2021 VS 2028

Table 22. By Region - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue (US\$, Mn), 2017-2022

Table 23. By Region - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue (US\$, Mn), 2023-2028

Table 24. By Region - Global Adalimumab, Infliximab And Etanercept Biosimilars Sales (K Units), 2017-2022

Table 25. By Region - Global Adalimumab, Infliximab And Etanercept Biosimilars Sales (K Units), 2023-2028

Table 26. By Country - North America Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - North America Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - North America Adalimumab, Infliximab And Etanercept Biosimilars Sales, (K Units), 2017-2022

Table 29. By Country - North America Adalimumab, Infliximab And Etanercept Biosimilars Sales, (K Units), 2023-2028

Table 30. By Country - Europe Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2017-2022

Table 31. By Country - Europe Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2023-2028

Table 32. By Country - Europe Adalimumab, Infliximab And Etanercept Biosimilars Sales, (K Units), 2017-2022

Table 33. By Country - Europe Adalimumab, Infliximab And Etanercept Biosimilars Sales, (K Units), 2023-2028

Table 34. By Region - Asia Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2017-2022

Table 35. By Region - Asia Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2023-2028

Table 36. By Region - Asia Adalimumab, Infliximab And Etanercept Biosimilars Sales, (K Units), 2017-2022

Table 37. By Region - Asia Adalimumab, Infliximab And Etanercept Biosimilars Sales, (K Units), 2023-2028

Table 38. By Country - South America Adalimumab, Infiximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2017-2022

Table 39. By Country - South America Adalimumab, Infiximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2023-2028

Table 40. By Country - South America Adalimumab, Infiximab And Etanercept Biosimilars Sales, (K Units), 2017-2022

Table 41. By Country - South America Adalimumab, Infiximab And Etanercept Biosimilars Sales, (K Units), 2023-2028

Table 42. By Country - Middle East & Africa Adalimumab, Infiximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2017-2022

Table 43. By Country - Middle East & Africa Adalimumab, Infiximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2023-2028

Table 44. By Country - Middle East & Africa Adalimumab, Infiximab And Etanercept Biosimilars Sales, (K Units), 2017-2022

Table 45. By Country - Middle East & Africa Adalimumab, Infiximab And Etanercept Biosimilars Sales, (K Units), 2023-2028

Table 46. Boehringer Ingelheim Corporate Summary

Table 47. Boehringer Ingelheim Adalimumab, Infiximab And Etanercept Biosimilars Product Offerings

Table 48. Boehringer Ingelheim Adalimumab, Infiximab And Etanercept Biosimilars Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)

Table 49. Abbvie Corporate Summary

Table 50. Abbvie Adalimumab, Infiximab And Etanercept Biosimilars Product Offerings

Table 51. Abbvie Adalimumab, Infiximab And Etanercept Biosimilars Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)

Table 52. Cipla Ltd Corporate Summary

Table 53. Cipla Ltd Adalimumab, Infiximab And Etanercept Biosimilars Product Offerings

Table 54. Cipla Ltd Adalimumab, Infiximab And Etanercept Biosimilars Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)

Table 55. Hetero Drugs Limited Corporate Summary

Table 56. Hetero Drugs Limited Adalimumab, Infiximab And Etanercept Biosimilars Product Offerings

Table 57. Hetero Drugs Limited Adalimumab, Infiximab And Etanercept Biosimilars Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)

Table 58. Pfizer Corporate Summary

Table 59. Pfizer Adalimumab, Infiximab And Etanercept Biosimilars Product Offerings

Table 60. Pfizer Adalimumab, Infiximab And Etanercept Biosimilars Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)

Table 61. Novartis Corporate Summary

Table 62. Novartis Adalimumab, Infliximab And Etanercept Biosimilars Product Offerings

Table 63. Novartis Adalimumab, Infliximab And Etanercept Biosimilars Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)

Table 64. Samsung Bioepis(Samsung Biologics) Corporate Summary

Table 65. Samsung Bioepis(Samsung Biologics) Adalimumab, Infliximab And Etanercept Biosimilars Product Offerings

Table 66. Samsung Bioepis(Samsung Biologics) Adalimumab, Infliximab And Etanercept Biosimilars Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)

Table 67. Amgen Corporate Summary

Table 68. Amgen Adalimumab, Infliximab And Etanercept Biosimilars Product Offerings

Table 69. Amgen Adalimumab, Infliximab And Etanercept Biosimilars Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)

Table 70. Celltrion Healthcare Corporate Summary

Table 71. Celltrion Healthcare Adalimumab, Infliximab And Etanercept Biosimilars Product Offerings

Table 72. Celltrion Healthcare Adalimumab, Infliximab And Etanercept Biosimilars Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)

Table 73. Mylan Corporate Summary

Table 74. Mylan Adalimumab, Infliximab And Etanercept Biosimilars Product Offerings

Table 75. Mylan Adalimumab, Infliximab And Etanercept Biosimilars Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)

Table 76. HETERO Corporate Summary

Table 77. HETERO Adalimumab, Infliximab And Etanercept Biosimilars Product Offerings

Table 78. HETERO Adalimumab, Infliximab And Etanercept Biosimilars Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)

Table 79. Glenmark Pharmaceuticals Corporate Summary

Table 80. Glenmark Pharmaceuticals Adalimumab, Infliximab And Etanercept Biosimilars Product Offerings

Table 81. Glenmark Pharmaceuticals Adalimumab, Infliximab And Etanercept Biosimilars Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)

Table 82. Emcure Pharmaceuticals Corporate Summary

Table 83. Emcure Pharmaceuticals Adalimumab, Infliximab And Etanercept Biosimilars Product Offerings

Table 84. Emcure Pharmaceuticals Adalimumab, Infliximab And Etanercept Biosimilars

Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)

Table 85. Adalimumab, Infliximab And Etanercept Biosimilars Production Capacity (K Units) of Key Manufacturers in Global Market, 2020-2022 (K Units)

Table 86. Global Adalimumab, Infliximab And Etanercept Biosimilars Capacity Market Share of Key Manufacturers, 2020-2022

Table 87. Global Adalimumab, Infliximab And Etanercept Biosimilars Production by Region, 2017-2022 (K Units)

Table 88. Global Adalimumab, Infliximab And Etanercept Biosimilars Production by Region, 2023-2028 (K Units)

Table 89. Adalimumab, Infliximab And Etanercept Biosimilars Market Opportunities & Trends in Global Market

Table 90. Adalimumab, Infliximab And Etanercept Biosimilars Market Drivers in Global Market

Table 91. Adalimumab, Infliximab And Etanercept Biosimilars Market Restraints in Global Market

Table 92. Adalimumab, Infliximab And Etanercept Biosimilars Raw Materials

Table 93. Adalimumab, Infliximab And Etanercept Biosimilars Raw Materials Suppliers in Global Market

Table 94. Typical Adalimumab, Infliximab And Etanercept Biosimilars Downstream

Table 95. Adalimumab, Infliximab And Etanercept Biosimilars Downstream Clients in Global Market

Table 96. Adalimumab, Infliximab And Etanercept Biosimilars Distributors and Sales Agents in Global Market

List Of Figures

LIST OF FIGURES

Figure 1. Adalimumab, Infliximab And Etanercept Biosimilars Segment by Type

Figure 2. Adalimumab, Infliximab And Etanercept Biosimilars Segment by Application

Figure 3. Global Adalimumab, Infliximab And Etanercept Biosimilars Market Overview: 2021

Figure 4. Key Caveats

Figure 5. Global Adalimumab, Infliximab And Etanercept Biosimilars Market Size: 2021 VS 2028 (US\$, Mn)

Figure 6. Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue, 2017-2028 (US\$, Mn)

Figure 7. Adalimumab, Infliximab And Etanercept Biosimilars Sales in Global Market: 2017-2028 (K Units)

Figure 8. The Top 3 and 5 Players Market Share by Adalimumab, Infliximab And Etanercept Biosimilars Revenue in 2021

Figure 9. By Type - Global Adalimumab, Infliximab And Etanercept Biosimilars Sales Market Share, 2017-2028

Figure 10. By Type - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue Market Share, 2017-2028

Figure 11. By Type - Global Adalimumab, Infliximab And Etanercept Biosimilars Price (US\$/Unit), 2017-2028

Figure 12. By Application - Global Adalimumab, Infliximab And Etanercept Biosimilars Sales Market Share, 2017-2028

Figure 13. By Application - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue Market Share, 2017-2028

Figure 14. By Application - Global Adalimumab, Infliximab And Etanercept Biosimilars Price (US\$/Unit), 2017-2028

Figure 15. By Region - Global Adalimumab, Infliximab And Etanercept Biosimilars Sales Market Share, 2017-2028

Figure 16. By Region - Global Adalimumab, Infliximab And Etanercept Biosimilars Revenue Market Share, 2017-2028

Figure 17. By Country - North America Adalimumab, Infliximab And Etanercept Biosimilars Revenue Market Share, 2017-2028

Figure 18. By Country - North America Adalimumab, Infliximab And Etanercept Biosimilars Sales Market Share, 2017-2028

Figure 19. US Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2017-2028

Figure 20. Canada Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2017-2028

Figure 21. Mexico Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2017-2028

Figure 22. By Country - Europe Adalimumab, Infliximab And Etanercept Biosimilars Revenue Market Share, 2017-2028

Figure 23. By Country - Europe Adalimumab, Infliximab And Etanercept Biosimilars Sales Market Share, 2017-2028

Figure 24. Germany Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2017-2028

Figure 25. France Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2017-2028

Figure 26. U.K. Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2017-2028

Figure 27. Italy Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2017-2028

Figure 28. Russia Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2017-2028

Figure 29. Nordic Countries Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2017-2028

Figure 30. Benelux Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2017-2028

Figure 31. By Region - Asia Adalimumab, Infliximab And Etanercept Biosimilars Revenue Market Share, 2017-2028

Figure 32. By Region - Asia Adalimumab, Infliximab And Etanercept Biosimilars Sales Market Share, 2017-2028

Figure 33. China Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2017-2028

Figure 34. Japan Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2017-2028

Figure 35. South Korea Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2017-2028

Figure 36. Southeast Asia Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2017-2028

Figure 37. India Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2017-2028

Figure 38. By Country - South America Adalimumab, Infliximab And Etanercept Biosimilars Revenue Market Share, 2017-2028

Figure 39. By Country - South America Adalimumab, Infliximab And Etanercept

Biosimilars Sales Market Share, 2017-2028

Figure 40. Brazil Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2017-2028

Figure 41. Argentina Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2017-2028

Figure 42. By Country - Middle East & Africa Adalimumab, Infliximab And Etanercept Biosimilars Revenue Market Share, 2017-2028

Figure 43. By Country - Middle East & Africa Adalimumab, Infliximab And Etanercept Biosimilars Sales Market Share, 2017-2028

Figure 44. Turkey Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2017-2028

Figure 45. Israel Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2017-2028

Figure 46. Saudi Arabia Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2017-2028

Figure 47. UAE Adalimumab, Infliximab And Etanercept Biosimilars Revenue, (US\$, Mn), 2017-2028

Figure 48. Global Adalimumab, Infliximab And Etanercept Biosimilars Production Capacity (K Units), 2017-2028

Figure 49. The Percentage of Production Adalimumab, Infliximab And Etanercept Biosimilars by Region, 2021 VS 2028

Figure 50. Adalimumab, Infliximab And Etanercept Biosimilars Industry Value Chain

Figure 51. Marketing Channels

I would like to order

Product name: Adalimumab, Infliximab And Etanercept Biosimilars Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/A4238D2DD30AEN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A4238D2DD30AEN.html>